Skip to main content
Premium Trial:

Request an Annual Quote

GT All-Stars, Next-Gen Sequencing, DiaDexus, NIH Roadmap, and Bioimaging

Premium

 

In 2003, Genome Technology celebrated its third annual All-Stars, our awards to scientists who were chosen by a panel of experts as the most deserving of recognition. That year, winners included George Church, Pat Brown, Lincoln Stein, Ruedi Aebersold, David Cox, Rolf Apweiler, Jeffrey Trent, and Francis Collins. Five years made quite a difference for many of them. Church has since launched his Personal Genomes Project and handed off his latest brainchild, a next-gen sequencing tool called the Polonator, for commercialization to manufacturing giant Danaher Motion. Stein accepted a position at the Ontario Institute for Cancer Research, headed up by Tom Hudson, and now spends most of his time there while continuing to maintain a presence at his longtime home of Cold Spring Harbor Laboratory. And Collins stepped down as director of NHGRI at the end of August.

Also in GT's November 2003 issue, we reported that NHGRI was launching a new grant program to fund development of technology to drastically reduce the cost of DNA sequencing. In the time since, the genome institute's awards have helped a number of researchers and companies develop next-gen sequencing tools. NHGRI recently made the last of its $100,000 genome awards, reasoning that by next year that goal will have been met. Indeed, some companies — including Applied Biosystems and Illumina — say that they've already sequenced a human genome for less than $100,000, and startup Complete Genomics has said that by next year it will be able to sequence a human genome for $5,000.

Five years ago, we also profiled DiaDexus, a genomics-based diagnostic company founded by Randy Scott and George Poste in 1997. Earlier this year, DiaDexus announced that it had received FDA clearance for an automated version of its test for stroke and heart disease susceptibility. Meantime, Scott is CEO of Genomic Health, which in 2004 launched OncotypeDX, a genomic test to predict chances for both recurrence and chemotherapy efficacy in breast cancer patients. Poste is director of the Biodesign Institute at Arizona State University, where he is also a professor of biology.

A year ago in GT, we reported that the Clinical Translational Science Awards consortium, founded by NIH in 2006, had been given a boost of $574 million over five years. The consortium is part of Elias Zerhouni's Roadmap Initiative, a program that has issued large amounts of funding for clinical and translational research. In this issue, we profile Oregon Clinical and Translational Research Institute, one of the first institutes to win a grant through the CTSA program.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more